Atrial fibrillation (AF) is associated with a 5-fold increase in the risk of ischemic stroke.1 Left atrial appendage (LAA) closure reduces the risk of stroke in non-valvular AF (NVAF) patients who are seeking an alternative to oral anticoagulants.2,3
2024 EUROPEAN SOCIETY OF CARDIOLOGY (ESC) GUIDELINES FOR THE MANAGEMENT OF ATRIAL FIBRILLATION DEVELOPED IN COLLABORATION WITH THE EUROPEAN ASSOCIATION OF CARDIOTHORACIC SURGERY (EACTS)4-7
ACCESS TO ALL TREATMENT OPTIONS FOR AF
Structured support for lifestyle changes
Anticoagulation
Rate control
CATHETER AND SURGICAL INTERVENTIONS (ABLATION, LAA OCCLUDER, AF SURGERY, ETC.)
Antiarrhythmic drugs
Complex management decisions underpinned by an AF Heart Team
|
|
|
|---|---|---|
Percutaneous LAA occlusion may be considered in patients with AF and contraindications for long-term anticoagulant treatment to prevent ischaemic stroke and thromboembolism. | IIb | C |
PROFESSOR HANS-CHRISTOPH DIENER
Prevention of stroke in patients with AF:
To learn more about the proof of concept studies that led to the current class IIb recommendation for LAAO in the management of AF, please click on the publication link below:
Diener H-C, Landmesser U. Percutaneous left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation.8
Connext
Live
Hear from the most respected KOLs in cardiovascular and stroke prevention, collaborate on best practice and be part of the CONNEXT community.
TV
Amplatzer™ Amulet™ LAA Occluder
Left Atrial Appendage Occlusion (LAAO)
Anatomical overview of the heart
LAAO Summit - Imaging debate: Mini TEE
LAAO Summit - New data & future trials
LAAO Summit - Debate: Factor XI inhibitors
LAAO Summit - Debate: Factor XI inhibitors
LAAO Summit - Imaging debate: TEE
LAAO Summit - Imaging debate: ICE
LAAO Summit - Pre-procedural imaging
HUB
PDL Analysis Summary
PDL Technical Analysis by Dr. Lakkiredy
Amulet IDE Results
LAAO Neuro Brochure
LAAO Referral Brochure
LAAO Patient Guide
Nephrologist LAA Therapy Deck
Clinical insights: Amulet™
Clinical insights: LAAO
Monitoring for AF prior to PFO closure
- Amplatzer™ Amulet™ LAA Occluder Instructions for Use.
- Lakkireddy D, Thaler D, Ellis CR, et al. Amplatzer Amulet Left Atrial Appendage Occluder versus Watchman device for stroke prophylaxis (Amulet IDE): A randomized controlled trial. Circulation. 2021; 144(19):1543–1552. doi.org/10.1161/CIRCULATIONAHA.121.057063.
- Suradi HS, Hijazi ZM. Left atrial appendage closure: outcomes and challenges. Neth Heart J. 2017;25(2):143–151. doi.org/10.1007/s12471-016-0929-0.
- Boersma LV, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E, et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: periprocedural outcomes from the EWOLUTION registry. Eur Heart J 2016;37:2465–74. doi.org/10.1093/eurheartj/ehv730
- Reddy VY, Mobius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study with Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol 2013;61:2551–6. doi.org/10.1016/j.jacc.2013.03.035
- Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, et al. Evaluating realworld clinical outcomes in atrial fibrillation patients receiving the WATCHMAN left atrial appendage closure technology: final 2–year outcome data of the EWOLUTION trial focusing on history of stroke and hemorrhage. Circ Arrhythm Electrophysiol 2019;12:e006841. doi.org/10.1161/CIRCEP.118.006841
- Tzikas A, Shakir S, Gafoor S, Omran H, Berti S, Santoro G, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER cardiac plug. EuroIntervention 2016;11:1170–9. doi.org/10.4244/EIJY15M01_06
- Diener H-C, Landmesser U. Percutaneous left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. Future Neurol. 2020;15(3).https://doi.org/10.2217/fnl-2020-0001.